ALKtALK with Dr. Ryohei Katayama: Combatting resistance and why ALK+ lung #cancer comes back

Dr. Ryohei Katayama, a leading cancer biologist whose groundbreaking research is shaping the future of targeted cancer therapy. Dr. Katayama specializes in molecular targeted therapy, drug resistance, and cancer metastasis, and he currently serves as the Chief of the Division of Experimental Chemotherapy at the Japanese Foundation for Cancer Research. His extensive work on ALK-positive non-small cell lung cancer (NSCLC) has provided crucial insights into mechanisms of drug resistance to ALK inhibitors. Notably, his research has demonstrated the potential of Gilteritinib, an ALK inhibitor, to overcome resistance in ALK-rearranged cancers, even in cases resistant to Lorlatinib.

Press PLAY to hear from Dr. Katayama as he shares his latest findings and advancements in the field, shedding light on strategies to combat drug resistance and improve treatment outcomes for cancer patients.

+ + + About our ALKtALKs and ALK Positive Inc + + +

ALKtALKs are our flagship community program aimed at making our ALK community a little smarter and a little smaller, by bringing the latest information, research and practices from leading experts.

ALK Positive does not endorse specific treatments and does not provide medical advice. Questions and concerns should be raised with individual care teams.

Our full range of Healing Arts classes help our community balance a productive life, treatment side effects and the mental stress of a cancer diagnosis.

📢 Follow us on social media & join the conversation online!

Facebook 📘 / alkpositivecancer
Instagram 📸 / alkpositiveinc
LinkedIn 💼 / alkpositivecancer
TikTok 🎵 / alkpositiveinc

[OncogeneCancerResearch]

Exciting to hear Dr Katayama speaking on his work and plans for Gilteritinib! We would love to see trials of this outside the US too. Thank you, ALK Positive 🎉